Vulnerable COPD patients with comorbidities: the role of roflumilast
Melissa Lipari1,2 Pramodini B Kale-Pradhan1,2 1Department of Pharmacy Practice, Wayne State University; 2St John Hospital and Medical Center, Detroit, MI, USA Abstract: Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that was approved by the US Food and Drug Administration in Febr...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-11-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/vulnerable-copd-patients-with-comorbidities-the-role-of-roflumilast-peer-reviewed-article-TCRM |